Amyloid Cardiomyopathy Clinical Trials
4 recruiting trials for Amyloid Cardiomyopathy. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Amyloid Cardiomyopathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 4 is the largest group at 50% (1 studies); the largest phase groups are Phase 4: 1, Phase 3: 1.
Research is led by IRCCS Azienda Ospedaliero-Universitaria di Bologna (1), Insel Gruppe AG, University Hospital Bern (1), Seoul St. Mary's Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Enavogliflozin 0.3mg (drug, 1 trial), followed by Placebo, Acoramidis.
Track Amyloid Cardiomyopathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with...
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced...
Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the...
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a...
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Amyloid Cardiomyopathy, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Amyloid Cardiomyopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Amyloid Cardiomyopathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.